BC Innovations | Dec 12, 2019
Distillery Therapeutics

Combined inhibition of CDK12 and CDK13 for TNBC

DISEASE CATEGORY: Cancer INDICATION: Breast cancer A Moffitt Cancer Center and Research Institute team showed that dual inhibition of CDK12 and CDK13 could treat triple-negative breast cancer (TNBC). In four human TNBC cell lines, an...
BC Innovations | Sep 12, 2019
Distillery Therapeutics

Tumor-targeted serum albumin-chemotherapy conjugates for improved delivery to breast and colorectal cancers

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; colorectal cancer Delivering chemotherapies through conjugation to tumor-targeted albumin could treat breast and colorectal cancers. Albumin is fused with collagen-binding domain of vWF to facilitate attachment to the tumor...
BC Innovations | Aug 22, 2019
Translation in Brief

Systems biology orders strategy to avoid cross-drug resistance in cancer

A Harvard and Mitra Biotech team used systems biology to identify a temporal treatment regimen that uses a glucose metabolism inhibitor to overcome cross-drug resistance in breast cancer. Chemotherapies are often administered in combination regimens...
BC Extra | Aug 17, 2019
Financial News

Aug. 16 Financial Quick Takes: Trio of IPO filings; plus Bellicum, Generex

SpringWorks, Satsuma, Monopar propose IPOs  SpringWorks Therapeutics Inc. (Stamford, Conn.), Satsuma Pharmaceuticals Inc. (South San Francisco, Calif.) and Monopar Therapeutics Inc. (Northbrook, Ill.) are looking to go public on NASDAQ. SpringWorks proposed to raise up...
BioCentury | Jun 29, 2019

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BC Innovations | Jun 7, 2019
Translation in Brief

Binding the extracellular matrix to target brain tissue

Attaching biologics to an antigen receptor derived from a fish that preferentially binds the brain's extracellular matrix could enable targeted drug delivery to the CNS. A University of Wisconsin-Madison team found that lamprey-derived immune molecules...
BC Innovations | Jun 4, 2019
Distillery Therapeutics

Targeting brain extracellular matrix to improve doxorubicin efficacy in GBM

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Cell culture and mouse studies suggest doxorubicin-loaded nanoparticles targeted to brain extracellular matrix (ECM) could help treat glioblastoma multiforme (GBM). The nanoparticles consist of doxorubicin-loaded liposomes chemically linked to...
BC Extra | May 29, 2019
Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
BC Extra | Apr 25, 2019
Company News

Lilly pulling Lartruvo after failure in confirmatory study

Following the failure in January of Lartruvo olaratumab to show a survival benefit in a confirmatory study, Lilly now intends to withdraw the drug from the market. Since 2016, Lartruvo has been approved to treat...
BC Innovations | Apr 22, 2019
Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
Items per page:
1 - 10 of 1518